Skip to search formSkip to main contentSkip to account menu

MLN2238

Known as: MLN-2238 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Boron CompoundsGlycineixazomib
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma
The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can… 
2014
2014
MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA
Patients undergoing androgen blockade therapy develop castration-resistant prostate cancer (CRPC), which is associated with Bcl-2… 
2014
2014
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in the U.S. The course of the disease has been… 
Review
2013
Review
2013
Proteasome inhibitors in acute leukemia
Proteasome inhibition has been recognized as a novel treatment modality in hematologic malignancies. Initially, the reversible… 
2013
2013
The Novel Proteasome Inhibitor MLN2238 (Ixazomib) Induces Death In CLL Cells In Vitro and Potentiates Lethality Of Fludarabine and The BCL2 Inhibitor At-101
Background Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of clonal B cells in the peripheral blood… 
2012
2012
Abstract 5669: Mechanisms of activity and drug resistance with proteasome inhibitors in multiple myeloma: Comparison of bortezomib and the investigational drug MLN9708
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Therapy with proteasome inhibitors… 
Review
2012
Review
2012
227 Association of K-Ras Genotype with Xenograft Tumor Response to the Investigational Proteasome Inhibitor MLN9708
2010
2010
An Investigational Proteasome Inhibitor MLN9708 (MLN2238) Induces Apoptosis In Human Multiple Myeloma Cells In Vitro
Abstract 3066 Targeting the proteasome has proven to be one of the most effective therapeutic strategies in the treatment of… 
2009
2009
Antitumor Activity of MLN9708, a Second-Generation Proteasome Inhibitor, in Preclinical Models of Lymphoma.
Abstract 3724 Poster Board III-660 Lymphomas account for about 5% of all cases of cancer in the US. In 2009, it is estimated that… 
2009
2009
In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer.
Abstract Abstract 2709 Poster Board II-685 Introduction: The ubiquitin-proteasome system processes the majority of cellular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)